Full Text
Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients

Abstract

Authors

V.P. Retèl L.M.G. Steuten J.C. Mewes W.H. van Harten

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×